G. Schaefer

发表

Prostate cancer diagnosis: value of real-time elastography

G. Bartsch, L. Pallwein, F. Aigner, 2008, Abdominal Imaging.

Targeted high throughput sequencing in clinical cancer Settings: formaldehyde fixed-paraffin embedded (FFPE) tumor tissues, input amount and tumor heterogeneity

Ralf Herwig, Hans Lehrach, Holger Sültmann, 2011, BMC Medical Genomics.

Tubulin tyrosine ligase like 12 links to prostate cancer through tubulin posttranslational modification and chromosome ploidy

H. Klocker, J. Schalken, G. Schaefer, 2010, International journal of cancer.

MALDI-MS tissue imaging identification of biliverdin reductase B overexpression in prostate cancer.

H. Klocker, S. Rauser, A. Walch, 2013, Journal of proteomics.

Effect of Urinary Cytology for Detecting Recurrence in Remnant Urothelium After Radical Cystectomy: Insights From a 10‐year Cytology Database

W. Horninger, G. Schaefer, W. Oberaigner, 2017, Clinical genitourinary cancer.

Under diagnosis and over diagnosis of prostate cancer in a screening population with serum PSA 2 to 10 ng/ml.

G. Bartsch, W. Horninger, G. Schaefer, 2007, The Journal of urology.

A hormone-dependent feedback-loop controls androgen receptor levels by limiting MID1, a novel translation enhancer and promoter of oncogenic signaling

Helmut Klocker, Andrea Köhler, Rainer Schneider, 2014, Molecular Cancer.

EpCAM overexpression is associated with high-grade urothelial carcinoma in the renal pelvis.

G. Schaefer, A. Brunner, C. Ensinger, 2008, Anticancer research.

Distinct ERG rearrangement prevalence in prostate cancer: higher frequency in young age and in low PSA prostate cancer

M. Rubin, H. Klocker, J. Mosquera, 2013, Prostate Cancer and Prostatic Disease.

Serum Autoantibodies in Chronic Prostate Inflammation in Prostate Cancer Patients

M. Rubin, H. Klocker, A. Lueking, 2016, PloS one.

The Glucocorticoid Receptor Is a Key Player for Prostate Cancer Cell Survival and a Target for Improved Antiandrogen Therapy

H. Klocker, G. Schaefer, C. Ploner, 2017, Clinical Cancer Research.

Identification of functionally active, low frequency copy number variants at 15q21.3 and 12q21.31 associated with prostate cancer risk

John T. Wei, M. Rubin, A. Chinnaiyan, 2012, Proceedings of the National Academy of Sciences.

Differential radioactive quantification of protein abundance ratios between benign and malignant prostate tissues: Cancer association of annexin A3

H. Klocker, K. Dietz, G. Schaefer, 2007, Proteomics.

Targeting the glucocorticoid receptor signature gene Mono Amine Oxidase-A enhances the efficacy of chemo- and anti-androgen therapy in advanced prostate cancer

H. Klocker, H. Hackl, G. Schaefer, 2021, Oncogene.

Characterization of normal and malignant prostate tissue by Fourier transform infrared microspectroscopy.

Georg Bartsch, Helmut Klocker, Christian W Huck, 2010, Molecular bioSystems.

Angiogenesis in nodal B cell lymphomas: a high throughput study

G. Schaefer, M. Fiegl, S. Ebner, 2006, Journal of Clinical Pathology.

Splice variant transcripts of the anterior gradient 2 gene as a marker of prostate cancer

H. Klocker, W. Parson, G. Schaefer, 2014, Oncotarget.

Evaluation of the PI-RADS scoring system for mpMRI of the prostate: a whole-mount step-section analysis

Werner Jaschke, Michael Edlinger, U. Nagele, 2015, World Journal of Urology.

Urinary UBC Rapid and NMP22 Test for Bladder Cancer Surveillance in Comparison to Urinary Cytology: Results from a Prospective Single-Center Study

W. Horninger, G. Schaefer, R. Pichler, 2017, International journal of medical sciences.

The STAT3 Inhibitor Galiellalactone Reduces IL6-Mediated AR Activity in Benign and Malignant Prostate Models

F. Claessens, G. Schaefer, W. V. van Weerden, 2018, Molecular Cancer Therapeutics.

A hormone-dependent feedback-loop controls androgen receptor levels by limiting MID1, a novel translation enhancer and promoter of oncogenic signaling

H. Klocker, G. Schaefer, Clemens Achmüller, 2014, Molecular Cancer.

Pathological features of Gleason score 6 prostate cancers in the low and intermediate range of prostate‐specific antigen level: is there a difference?

G. Bartsch, W. Horninger, G. Schaefer, 2008, BJU international.

Breast carcinoma in elderly women: pathology, prognosis, and survival.

G. Schaefer, M. Lesser, E. Beattie, 1984, Pathology annual.

Value of magnetic resonance imaging in prostate cancer diagnosis

Alexandre Pelzer, Georg Bartsch, Ferdinand Frauscher, 2007, World Journal of Urology.

Advanced Vibrational Spectroscopic Imaging of Human Tissue in Life Science

H. Klocker, C. Huck, F. Kloss, 2012 .

424: Overexpression of the Anti-Apoptotic Protein MCL-1 is an Early Event in Prostate Cancer

H. Klocker, G. Bartsch, G. Schaefer, 2004 .

Clinical and pathological features of screen vs non‐screen‐detected prostate cancers: is there a difference?

G. Bartsch, W. Horninger, L. Pallwein, 2008, BJU international.

Over‐diagnosis and under‐diagnosis of screen‐ vs non‐screen‐detected prostate cancers with in men with prostate‐specific antigen levels of 2.0–10.0 ng/mL

G. Bartsch, W. Horninger, F. Aigner, 2008, BJU international.

The influence of prostate volume on prostate cancer detection using a combined approach of contrast‐enhanced ultrasonography‐targeted and systematic grey‐scale biopsy

G. Bartsch, W. Horninger, G. Schaefer, 2007, BJU international.

Upgrading of Gleason score 6 prostate cancers on biopsy after prostatectomy in the low and intermediate tPSA range

G. Bartsch, G. Schaefer, M. Mitterberger, 2008, Prostate Cancer and Prostatic Diseases.